PLIANT THERAPEUTICS, INC.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. The company's website is www.plianttx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PLIANT THERAPEUTICS, INC. does
In the company’s own words
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. The company's website is www.plianttx.com.
Pliant's lead product candidate, PLN-101095, is an oral small molecule dual selective inhibitor of αvβ8 and αvβ1 integrins in development for treating solid tumors resistant to immune checkpoint inhibitors. The company's approach targets transforming growth factor-beta (TGF-β) activation through integrin inhibition, with the goal of sensitizing tumors to checkpoint inhibitor therapies in heavily pretreated patient populations. In 2025, Pliant announced positive Phase 1 data demonstrating anti-tumor activity when PLN-101095 was combined with pembrolizumab, with clinical responses observed across multiple tumor types including cholangiocarcinoma, melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company has assembled a proprietary drug discovery platform consisting of a library containing over 15,000 integrin binding molecules, complemented by comprehensive screening assays and an advanced live human tissue program. Beyond its lead oncology program, Pliant is exploring integrin-based target-mediated drug delivery applications, with current early-stage programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells across multiple disease areas.
Pliant previously developed bexotegrast, an oral small molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins, for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company discontinued the Phase 2b BEACON-IPF trial in 2025 following an independent data safety monitoring board recommendation, though early efficacy signals were observed. The company continues evaluating development pathways for the PSC indication.
The company's intellectual property portfolio includes over 300 pending patent applications worldwide across more than 30 patent families, with fourteen U.S. patents and forty-four foreign patents issued as of March 2026. Patents are expected to expire between 2037 and 2047. All clinical manufacturing is outsourced to third-party contract manufacturing organizations, with drug substance supply established from Asian CMOs to support both clinical and preclinical requirements.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1746473
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PLIANT THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PLIANT THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PLIANT THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PLIANT THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PLIANT THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”